Pharmed
Bengaluru-based formulations maker with ₹529 Cr of FY25 revenue and ₹81 Cr profit, quoted around ₹820 on a ₹2 face value.
Market cap
₹353.11 Cr
0.43 Cr shares
P/E ratio
4.37
Sector average 28
Book value
₹689.38
P/B 1.19
1-year return
+0.00%
52w ₹820 – ₹820
Currently 0% of the way through its 52-week range.
Indicative price history
1Y change
+0.00% ₹820 → ₹820
52-week band in this window: ₹820.00 – ₹820.00. Weekly indicative marks, not exchange-traded prices.
Key highlights
- FY25 revenue ₹528.6 Cr and net profit ₹80.8 Cr, with EBITDA margin ~21%.
- Net profit up roughly 2.5x since FY23.
- ₹2 face value; about 43 lakh shares outstanding.
About Pharmed
Pharmed Limited is a 1946-vintage pharmaceutical company registered in Mumbai and run from Bengaluru, where its manufacturing and marketing operations are based. It makes branded generic formulations across cardiology, diabetology, gastroenterology and nutraceutical therapies and sells them through a domestic field force, with a growing contract-manufacturing and export book.
Dealer research summaries put FY25 revenue at ₹528.6 Cr with net profit of ₹80.8 Cr — roughly 2.5 times FY23 levels — and an EBITDA margin that expanded to about 21%. Tofler records operating revenue in the ₹100–500 Cr band for FY24 with EBITDA up 76% and net worth up 21%.
The share has a ₹2 face value with about 43.06 lakh shares outstanding. wwipl.com carries the stock (minimum 1,000 shares) but its last-traded figure was not retrievable; the ₹820 used here is the prevailing dealer quote, while Planify reported ₹697.80 in June 2026 with a one-year range of ₹580–1,000.
Figures preliminary; verify from MCA filings. Profit and revenue for FY25 are from dealer research; balance-sheet lines are estimates.
Where the revenue comes from
- Domestic branded formulations75%
Cardio-diabetic, GI and nutraceutical brands
- Contract manufacturing and exports20%
Third-party manufacturing and semi-regulated market exports
- Other5%
Trading and miscellaneous income
Products & services
Cardio-diabetic brands
Branded generics for hypertension, lipids and diabetes
GI and nutraceuticals
Gastro-intestinal formulations and nutritional supplements
Contract manufacturing
Third-party manufacturing for domestic and export clients
What works
- • Strong profitability: FY25 net margin of ~15% and EBITDA margin of ~21% on ₹529 Cr revenue.
- • Net profit has grown roughly 2.5x between FY23 and FY25, with net worth compounding alongside.
- • Small share count (43 lakh shares) means every rupee of earnings shows up as high EPS.
What to watch
- • The wwipl.com last-traded price was not retrievable; quotes across dealers range from ₹700 to ₹1,000, so the ₹820 used here is indicative only.
- • Share-count and paid-up data from public registries are inconsistent; the implied market value (~₹350 Cr at ₹820) should be re-derived from the annual return.
- • Registered office in Mumbai with operations in Bengaluru complicates registry checks; verify the ROC record before any transfer.
- • Illiquid stock with a 1,000-share minimum at some dealers.
Compare with peers
| Company | Price | Market cap | P/E | P/B | Rev CAGR |
|---|---|---|---|---|---|
| PharmedThis page | ₹820.00 | ₹353.11 Cr | 4.37 | 1.19 | +13.55% |
| Martin & Harris | ₹959.00 | ₹479.5 Cr | 11.99 | 1.88 | +9.92% |
| East India Pharma | ₹39.00 | ₹26.01 Cr | 5.91 | 0.43 | +7.88% |
Latest reported year: FY25 ending 31 Mar 2025.